Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intranasal Ketamine Clear all
Terminated Phase 3 Interventional

Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

NCT04150757
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis, Ketamine, Intranasal Ketamine, Analgesia
Interventions
Intranasal ketamine
Drug
Lead sponsor
Abigail Nixon
Other
Eligibility
3 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

NCT00520169
View directory record Official record
Conditions
Healthy
Interventions
intranasal ketamine
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures

NCT03466242
View directory record Official record
Conditions
Conscious Sedation, Distal Radius Fracture
Interventions
Dexmedetomidine, Ketamine
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional

Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

NCT06795659
View directory record Official record
Conditions
Post Traumatic Stress Disorder PTSD
Interventions
Esketamine (Intranasal Spray), Massed Prolonged Exposure (PE)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887
View directory record Official record
Conditions
Suicidal Ideation, Depression, Alcohol Abuse
Interventions
Intranasal ketamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03097133
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED

NCT05934669
View directory record Official record
Conditions
Laceration of Skin, Anxiety, Discharge Time
Interventions
Intranasal Midazolam, Intranasal Dexmedetomidine, Intranasal Ketamine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 5 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 5, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

NCT00492388
View directory record Official record
Conditions
Pain, Cancer
Interventions
PMI-150 (intranasal ketamine), placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Recruiting Phase 3 Interventional

Pain Control Alternatives in Pediatric Patients With Distal Radius Fractures

NCT07120763
View directory record Official record
Conditions
Distal Radius Fracture Reduction, Pain Control, Pediatric Fractures
Interventions
Ketamine + Lidocaine, Ketamine group, Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
3 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

NCT02611921
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair

NCT00451724
View directory record Official record
Conditions
Laceration
Interventions
Intranasal ketamine
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
1 Year to 7 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Sep 5, 2026, 5:47 PM EDT
Withdrawn Early Phase 1 Interventional

Intranasal Ketamine for Suicidal Ideation in Veterans

NCT03788694
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine
Drug
Lead sponsor
Bronx Veterans Medical Research Foundation, Inc
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 5, 2026, 5:47 PM EDT
Not listed Phase 4 Interventional

Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

NCT03221569
View directory record Official record
Conditions
Migraine
Interventions
Intravenous ketamine, Ketorolac, Normal saline
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

NCT00709436
View directory record Official record
Conditions
Pain, Postoperative
Interventions
PMI-150 (intranasal ketamine), Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Florence, Alabama • Sheffield, Alabama + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
View directory record Official record
Conditions
Treatment Resistant Depressive Disorder
Interventions
Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 64 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Withdrawn Phase 4 Interventional

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

NCT05554627
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 5, 2026, 5:47 PM EDT
Recruiting No phase listed Observational

The OBSERVE Protocol

NCT06725277
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Spravato, IV Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

NCT02846519
View directory record Official record
Conditions
Healthy
Interventions
Esketamine, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

NCT02682225
View directory record Official record
Conditions
Drug Abuse
Interventions
Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 5, 2026, 5:47 PM EDT
Recruiting No phase listed Observational

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Obsessive-Compulsive Disorder
Interventions
Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine, Esketamine, Deep Transcranial Magnetic Stimulation (dTMS)
Device · Drug
Lead sponsor
Mark Niciu
Other
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 5, 2026, 5:47 PM EDT